Literature DB >> 1823144

Evidence for plasticity of the dopaminergic system in parkinsonism.

G A Donnan1, D G Woodhouse, S J Kaczmarczyk, J E Holder, G Paxinos, P J Chilco, A J Churchyard, R M Kalnins, G C Fabinyi, F A Mendelsohn.   

Abstract

A series of compensatory mechanisms within the dopaminergic system have been shown to maintain clinical function in the presence of dopamine loss. Experimental evidence for increased presynaptic dopamine turnover owing to increased dopamine synthesis, release, and reduced reuptake exists. Direct evidence that these mechanisms maintain extracellular dopamine levels is provided by intracerebral microdialysis techniques. Postsynaptic denervation supersensitivity clearly occurs with D2 dopamine receptors, although this is less evident with D1 receptors. Similarly, mechanisms of plasticity have been shown to be relevant in human postmortem and Positron Emission Tomographic studies of patients with Parkinson's disease. However, although presynaptic increases in dopamine turnover are well documented, postsynaptic D1 and D2 receptor changes have been more difficult to establish, mainly because of methodological difficulties. D2, but not D1, receptor increases have been documented in drug naive Parkinsonian patients with PET techniques. In transplantation of adrenal gland to striatum in animal models and patients with Parkinsonism where clinical improvement occurs, plasticity of host response may be as important as plasticity of the graft. Although some elements of the compensatory mechanism of dopamine plasticity may be deleterious, such as dyskinesias owing to dopamine receptor supersensitivity, the overall effect of delay and minimization of the clinical expression of disease is advantageous. An even greater understanding of the mechanisms involved may assist in developing future therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1823144     DOI: 10.1007/BF02935563

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  81 in total

1.  Neurotransmitter regulation of neuronal outgrowth, plasticity and survival.

Authors:  S A Lipton; S B Kater
Journal:  Trends Neurosci       Date:  1989-07       Impact factor: 13.837

2.  Enzymes associated with the metabolism of catecholamines, acetylcholine and gaba in human controls and patients with Parkinson's disease and Huntington's chorea.

Authors:  P L McGeer; E G McGeer
Journal:  J Neurochem       Date:  1976-01       Impact factor: 5.372

3.  Primate neostriatal neurons containing tyrosine hydroxylase: immunohistochemical evidence.

Authors:  M Dubach; R Schmidt; D Kunkel; D M Bowden; R Martin; D C German
Journal:  Neurosci Lett       Date:  1987-03-31       Impact factor: 3.046

4.  Specific stimulation of in vitro maturation of mesencephalic dopaminergic neurones by striatal membranes.

Authors:  A Prochiantz; M C Daguet; A Herbet; J Glowinski
Journal:  Nature       Date:  1981 Oct 15-21       Impact factor: 49.962

5.  BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra.

Authors:  C Hyman; M Hofer; Y A Barde; M Juhasz; G D Yancopoulos; S P Squinto; R M Lindsay
Journal:  Nature       Date:  1991-03-21       Impact factor: 49.962

6.  Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease.

Authors:  U K Rinne; A Laihinen; J O Rinne; K Någren; J Bergman; U Ruotsalainen
Journal:  Mov Disord       Date:  1990       Impact factor: 10.338

7.  Adrenal medullary implants in the dopamine-denervated rat striatum. I. Acute catecholamine levels in grafts and host caudate as determined by HPLC-electrochemistry and fluorescence histochemical image analysis.

Authors:  I Strömberg; M Herrera-Marschitz; L Hultgren; U Ungerstedt; L Olson
Journal:  Brain Res       Date:  1984-04-09       Impact factor: 3.252

8.  Basic Fibroblast Growth Factor in the Adrenal Gland.

Authors:  Dieter Blottner; Reiner Westermann; Claudia Grothe; Peter Böhlen; Klaus Unsicker
Journal:  Eur J Neurosci       Date:  1989-09       Impact factor: 3.386

9.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice.

Authors:  R E Heikkila; A Hess; R C Duvoisin
Journal:  Science       Date:  1984-06-29       Impact factor: 47.728

10.  Striatal dopamine distribution in parkinsonian patients during life.

Authors:  C Nahmias; E S Garnett; G Firnau; A Lang
Journal:  J Neurol Sci       Date:  1985-07       Impact factor: 3.181

View more
  4 in total

Review 1.  The effects of prenatal alcohol exposure on behavior: rodent and primate studies.

Authors:  Mary L Schneider; Colleen F Moore; Miriam M Adkins
Journal:  Neuropsychol Rev       Date:  2011-04-19       Impact factor: 7.444

Review 2.  Role of dopamine receptors in ADHD: a systematic meta-analysis.

Authors:  Jing Wu; Haifan Xiao; Hongjuan Sun; Li Zou; Ling-Qiang Zhu
Journal:  Mol Neurobiol       Date:  2012-05-19       Impact factor: 5.590

3.  The acute toxic and neurotoxic effects of 3,4-methylenedioxymethamphetamine are more pronounced in adolescent than adult mice.

Authors:  Neha Milind Chitre; Monique Simone Bagwell; Kevin Sean Murnane
Journal:  Behav Brain Res       Date:  2019-12-03       Impact factor: 3.332

4.  Pramipexole, a Dopamine D2/D3 Receptor-Preferring Agonist, Prevents Experimental Autoimmune Encephalomyelitis Development in Mice.

Authors:  Vicente Lieberknecht; Stella C Junqueira; Mauricio P Cunha; Thaís A Barbosa; Luiz F de Souza; Igor S Coelho; Adair R S Santos; Ana Lúcia S Rodrigues; Alcir L Dafré; Rafael C Dutra
Journal:  Mol Neurobiol       Date:  2016-01-22       Impact factor: 5.590

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.